Compare VanEck Rare Earth/Strategic Metals (REMX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Recursion Pharmaceuticals Inc — how do they compare? VanEck Rare Earth/Strategic Metals trades at $75, while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). The key difference: VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REMX | RXRX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $6.79 |
52-Week Low | $57.35 | $2.84 |
Market Cap | — | $1.74B |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $76.72, up 1.4% on the day, but technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The ETF provides exposure to 38 global rare earth and strategic metals companies, with significant volatility and high turnover, as noted by Seeking Alpha on 2026-07-14. Recent news highlights strategic importance due to U.S. efforts to secure critical mineral supply chains, with Bank of America increasing its holdings significantly in the latest quarter.
The outlook for REMX is shaped by geopolitical tailwinds from U.S. supply chain initiatives but tempered by high volatility and China-dependent holdings. Investment appeal lies in diversification for commodities exposure, yet risks include export controls, market churn, and reliance on policy shifts. Analyst sentiment is cautious due to the ETF's speculative nature and operational risks.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
